A randomized controlled trial compared coronary artery plaque progression after androgen deprivation therapy using relugolix vs leuprolide in men with prostate cancer.
Atom Therapeutics, a clinical stage biotechnology company developing best-in-class treatments for inflammatory and metabolic diseases, today announced FDA approval of a Phase II clinical trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback